BioRestorative Therapies, Inc. (BRTX)

US — Healthcare Sector
Peers: PULM  CAPR  AKTX  DFFN  SLNO  PPCBD  CVKD  BBIXF  NVIV  CINGW  SABS  ANEB  MNPR  CANF  CADL  XTLB  CING  ACHV  BPTH  ICVX 

Automate Your Wheel Strategy on BRTX

With Tiblio's Option Bot, you can configure your own wheel strategy including BRTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol BRTX
  • Rev/Share 0.0468
  • Book/Share 0.7353
  • PB 2.421
  • Debt/Equity 0.0
  • CurrentRatio 2.237
  • ROIC -1.9941

 

  • MktCap 13359259.0
  • FreeCF/Share -1.0527
  • PFCF -1.5185
  • PE -1.2299
  • Debt/Assets 0.0
  • DivYield 0
  • ROE -1.3642

 

  • Rating D+
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 2
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Phase 2 Trial of BRTX-100 in cLDD Continues to Generate Positive Preliminary Blinded Data
BRTX
Published: May 13, 2025 by: GlobeNewsWire
Sentiment: Neutral

MELVILLE, N.Y., May 13, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, is pleased to announce that preliminary 26-, 52- and 104-week blinded preliminary data from the first 15 patients with chronic lumbar disc disease (“cLDD”) enrolled in the ongoing Phase 2 clinical trial of BRTX-100 was recently presented by Francisco Silva, Vice President of Research and Development, at the International Society for Cell & Gene Therapy (“ISCT”) 2025 Annual Meeting.

Read More
image for news Phase 2 Trial of BRTX-100 in cLDD Continues to Generate Positive Preliminary Blinded Data
Phase 2 Trial of BRTX-100 in cLDD Continues to Generate Positive Preliminary Blinded Data
BRTX
Published: May 13, 2025 by: GlobeNewsWire
Sentiment: Neutral

MELVILLE, N.Y., May 13, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, is pleased to announce that preliminary 26-, 52- and 104-week blinded preliminary data from the first 15 patients with chronic lumbar disc disease (“cLDD”) enrolled in the ongoing Phase 2 clinical trial of BRTX-100 was recently presented by Francisco Silva, Vice President of Research and Development, at the International Society for Cell & Gene Therapy (“ISCT”) 2025 Annual Meeting.

Read More
image for news Phase 2 Trial of BRTX-100 in cLDD Continues to Generate Positive Preliminary Blinded Data
BioRestorative to Present a BRTX-100 Clinical Update at ISCT 2025
BRTX
Published: May 07, 2025 by: GlobeNewsWire
Sentiment: Neutral

MELVILLE, N.Y., May 07, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, is pleased to announce that its Vice President of Research and Development, Francisco Silva, will present an update on its ongoing Phase 2 clinical trial of BRTX-100 in chronic lumbar disc disease (cLDD) at the International Society for Cell & Gene Therapy (“ISCT”) 2025 Annual Meeting, taking place May 7 - 10, 2025 in New Orleans, LA.

Read More
image for news BioRestorative to Present a BRTX-100 Clinical Update at ISCT 2025
BioRestorative Confirms No Material Impact from Reciprocal Tariffs; All BRTX-100 Production & Manufacturing Performed in the United States
BRTX
Published: April 10, 2025 by: GlobeNewsWire
Sentiment: Neutral

MELVILLE, N.Y., April 10, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, is pleased to confirm that it currently faces no material exposure to newly imposed U.S. tariffs.

Read More
image for news BioRestorative Confirms No Material Impact from Reciprocal Tariffs; All BRTX-100 Production & Manufacturing Performed in the United States
BioRestorative Announces Updated Time for February 27th Webcasted Conference Call to Discuss Clinical Pipeline Update
BRTX
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral

MELVILLE, N.Y., Feb. 26, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, announced today that it has changed the time for its previously announced webcasted conference call to discuss its pipeline update. The Company will now host the call at 10:30am EST on Thursday, February 27, 2025.

Read More
image for news BioRestorative Announces Updated Time for February 27th Webcasted Conference Call to Discuss Clinical Pipeline Update

About BioRestorative Therapies, Inc. (BRTX)

  • IPO Date 2012-12-05
  • Website https://www.biorestorative.com
  • Industry Biotechnology
  • CEO Mr. Lance Alstodt
  • Employees 11
BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is based in Melville, New York.